Agios Pharma (AGIO) Reiterated at Overweight by Cantor Fitzgerald as PDUFA Date Approaches
Tweet Send to a Friend
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Agios Pharma (NASDAQ: AGIO).The analyst commented, "The drug's PDUFA date ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




